Drug Profile
Felzartamab - MorphoSys
Alternative Names: HIB-202; MOR 202; MOR-03087; TJ-202Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator MorphoSys
- Developer Human Immunology Biosciences; I-MAB Biopharma; MorphoSys
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Preregistration Multiple myeloma
- Phase II IgA nephropathy; Membranous glomerulonephritis; Renal transplant rejection
- Phase I Lupus nephritis; Systemic lupus erythematosus
- No development reported Leukaemia
- Discontinued Non-small cell lung cancer
Most Recent Events
- 21 Mar 2024 Felzartamab - MorphoSys receives Orphan Drug status for Renal transplant rejection in USA
- 04 Mar 2024 I-MAB Biopharma plans a phase-I trial (In volunteers) in China (IV) (NCT06285201),
- 31 Oct 2023 Felzartamab - MorphoSys receives Breakthrough Therapy status for Membranous glomerulonephritis in USA